文献速递痛风与晶体性关节病

痛风急性发作药物干预的疗效与安全性:系统综述与网络荟萃分析

Efficacy and Safety of Pharmacologic Interventions in Patients Experiencing a Gout Flare: A Systematic Review and Network Meta-Analysis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2021-01-01

该系统综述与网络荟萃分析纳入30项随机对照试验,比较痛风急性发作时抗炎药物的相对疗效与安全性。结果显示,卡那单抗在第2天及最长随访时疼痛缓解最优,静脉或肌注糖皮质激素可能次之;醋酸类NSAIDs在关节肿胀和患者总体评估上可能优于布洛芬类NSAIDs。

要点

  • 卡那单抗在第2天及最长随访时疼痛缓解可能最优,证据确定性中等。
  • 静脉或肌注糖皮质激素可能为疼痛缓解第二优选择,证据确定性低至极低。
  • 醋酸类NSAIDs在第2天关节肿胀和最长随访PtGA上可能优于布洛芬类NSAIDs。

核心结论

  • 卡那单抗在痛风急性发作疼痛缓解上可能优于其他药物,静脉或肌注糖皮质激素可能次之。
  • 醋酸类NSAIDs在关节肿胀和患者总体评估上可能优于布洛芬类NSAIDs。

研究设计与样本

  • 研究为系统综述与频率学派框架网络荟萃分析,纳入30项比较痛风急性发作药物抗炎治疗的随机对照试验。
  • 检索Ovid Medline、Embase和Cochrane library,并使用GRADE for NMA评估证据确定性。

主要发现

  • 卡那单抗第2天疼痛评分相对醋酸类NSAIDs的平均差为-41.12(95%CI -53.36,-29.11,0-100量表),最长随访平均差为-12.84(95%CI -20.76,-4.91),均中等确定性,最小重要差值为-19。
  • 第2天关节压痛方面卡那单抗可能最有效。
  • 醋酸类NSAIDs第2天关节肿胀优于布洛芬类NSAIDs,平均差-0.29(95%CI -0.56,-0.02,0-4量表,中等确定性)。
  • 醋酸类NSAIDs最长随访PtGA优于布洛芬类NSAIDs,平均差-0.44(95%CI -0.86,-0.02,中等确定性)。
  • 静脉或肌注糖皮质激素劣于卡那单抗但可能优于其他常用干预(低至极低确定性)。

关键数值与推荐

  • 疼痛缓解最优为卡那单抗,第2天平均差-41.12(95%CI -53.36,-29.11),最长随访-12.84(95%CI -20.76,-4.91),最小重要差值-19。
  • 关节肿胀醋酸类NSAIDs优于布洛芬类NSAIDs,平均差-0.29(95%CI -0.56,-0.02,0-4量表)。
  • PtGA醋酸类NSAIDs优于布洛芬类NSAIDs,平均差-0.44(95%CI -0.86,-0.02)。

临床怎么用

  • 痛风急性发作疼痛缓解可优先考虑卡那单抗,静脉或肌注糖皮质激素可作为次选。
  • 选择NSAIDs时,醋酸类NSAIDs在关节肿胀和患者总体评估上可能优于布洛芬类NSAIDs。

局限性

  • 静脉或肌注糖皮质激素相关比较的证据确定性为低至极低。
  • 卡那单抗与醋酸类NSAIDs的比较证据确定性为中等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the relative efficacy and safety of pharmacologic antiinflammatory interventions for gout flares. METHODS: We searched Ovid Medline, Embase, and Cochrane library for randomized controlled trials (RCTs) that compared pharmacologic antiinflammatory treatment of gout flares. We conducted a network meta-analysis (NMA) using a frequentist framework and assessed the certainty of evidence and made conclusions using the Grading of Recommendations Assessment, Development, and Evaluation for NMA. RESULTS: In the 30 eligible RCTs, canakinumab provided the highest pain reduction at day 2 and at longest follow-up (mean difference relative to acetic acid derivative nonsteroidal antiinflammatory drugs [NSAIDs] -41.12 [95% confidence interval (95% CI) -53.36, -29.11] on a 0-100 scale at day 2, and mean difference -12.84 [95% CI -20.76, -4.91] at longest follow-up; both moderate certainty; minimum important difference -19). Intravenous or intramuscular corticosteroids were inferior to canakinumab but may be better than the other commonly used interventions (low to very low certainty). For joint tenderness, canakinumab may be the most effective intervention at day 2. Acetic acid derivative NSAIDs improved joint swelling better than ibuprofen NSAIDs at day 2 (mean difference -0.29 [95% CI -0.56, -0.02] on a 0-4 scale; moderate certainty) and improved patient global assessment (PtGA) greater than ibuprofen NSAIDs at the longest follow-up (mean difference -0.44 [95% CI -0.86, -0.02]; moderate). CONCLUSION: Canakinumab may be superior to other alternatives and intravenous or intramuscular corticosteroids may be the second best in pain reduction. Acetic acid derivative NSAIDs may be superior to ibuprofen NSAIDs in improving joint swelling and PtGA.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Zeng L, Qasim A, Neogi T, et al. Efficacy and Safety of Pharmacologic Interventions in Patients Experiencing a Gout Flare: A Systematic Review and Network Meta-Analysis. Arthritis Care Res (Hoboken). 2021. PMID: 32741131. doi:10.1002/acr.24402

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。